MedPath

Lifestyle Interventions for the Treatment of Non-alcoholic Fatty Liver Disease in Overweight and Obese Adults

Not Applicable
Conditions
Obesity
Non-Alcoholic Fatty Liver Disease
Interventions
Behavioral: Lifestyle education
Behavioral: Intensive lifestyle intervention
Behavioral: Hypocaloric low-carbohydrate diet plan
Registration Number
NCT03972631
Lead Sponsor
First Affiliated Hospital of Zhejiang University
Brief Summary

Lifestyle intervention is the most important management of non-alcoholic fatty liver diseases (NAFLD) patients. Weight reductions of 5-10% can improve non-alcoholic steatosis and fibrosis. However, the options for treatment in the clinics are limited. Therefore, in this study, we investigated the effectiveness of different lifestyle intervention strategies in NAFLD patients.

Detailed Description

This is a multicenter, randomized clinical trial nested within a cohort study in overweight and obese non-alcoholic fatty liver diseases (NAFLD) patients. In this study, 1500 eligible patients will be recruited, and demographic information and clinical data will be collected at baseline. Among these, 292 participants who agree to be randomized will be randomized into two intervention groups, including lifestyle education (LE), and intensive lifestyle intervention with low-carbohydrate diet (ILI), aiming to induce a loss ≥ 10% of initial weight in 3 months. The remainder will chose the treatment which they prefer according to the clinical practice. At the 3th, 6th and 12th month, all the participants will be followed, and data will be collected to study the development of NAFLD in different lifestyle intervention groups.

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
292
Inclusion Criteria
  • Man or women aged 18-65 years;
  • Confirmed diagnosis of NAFLD according to the 2018 Chinese Guidelines for Prevention and Treatment of NAFLD;
  • Body mass index (BMI)of 25.0 to 35.0 kg/m2;
  • Patients without medicine for treatment of NAFLD;
Exclusion Criteria
  • Patients with other diseases that can lead to fatty liver;
  • Patients use amiodaron, methotrexate, tamoxifen, glucocorticoid, estrogen, and the other medications that affect weight within 3 months;
  • Patients with serious liver dysfunction (AST or/and ALT >3 times of the upper limit of normal), or renal dysfunction (serum creatinine >the upper limit of normal);
  • Patients with diseases that need control of dietary protein intake;
  • Patients with diseases that affect food digestion and absorption;
  • Patients with diagnosed diabetes or those with significantly elevated blood glucose (fasting blood glucose ≥7.0 mmol/L and/or random blood glucose ≥11.1 mmol/L);
  • Patients with severe cardiovascular and cerebrovascular diseases or severe hypertension (Grade 3); anemia; mental illness or memory disorder; epilepsy or antiepileptic treatment;
  • Patients with secondary obesity;
  • Patients with cancer, active tuberculosis, AIDS and other infectious diseases;
  • Pregnancy or lactation;
  • Physical disability.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Lifestyle educationLifestyle educationThe participants in this group will be provided usual recommendation, including the diet principles, activity guideline and behavioral strategies at baseline. In addition, the participants will have access to an APP, with which the participants could learn more information of body weight management, and keep records of diet, activity and body weight during the study.
Intensive Lifestyle InterventionLifestyle educationThe participants in this group will be provided a comprehensive intervention, including goal setting, one to one support by the lifestyle counselors, and meal replacement products, in addition to the information and APP which are provided to the Lifestyle education group.
Intensive Lifestyle InterventionHypocaloric low-carbohydrate diet planThe participants in this group will be provided a comprehensive intervention, including goal setting, one to one support by the lifestyle counselors, and meal replacement products, in addition to the information and APP which are provided to the Lifestyle education group.
Intensive Lifestyle InterventionIntensive lifestyle interventionThe participants in this group will be provided a comprehensive intervention, including goal setting, one to one support by the lifestyle counselors, and meal replacement products, in addition to the information and APP which are provided to the Lifestyle education group.
Primary Outcome Measures
NameTimeMethod
Liver Stiffness Measurementbaseline, 3 month

LSM is suggested as degree of liver fibrosis

Change in liver function biomarkersbaseline, 3 month

ALT, AST

Change in BMIbaseline, 3 month
Fast Ultrasound Attenuation Parameterbaseline, 3 month

FAP is suggested as degree of liver steatosis.

Secondary Outcome Measures
NameTimeMethod
Change in glycemic markersbaseline, 3 month

fasting glucose, fasting insulin, HbA1C

Change in body compositionbaseline, 3 month

muscle mass, fat percentage

Change in BMI6 month, 12 month
Change in blood pressurebaseline, 3 month
Change in liver function biomarkers6 month, 12 month

ALT, AST

Change in lipidbaseline, 3 month

triglyceride, total cholesterol , LDL-C, and HDL-C

© Copyright 2025. All Rights Reserved by MedPath